AC Immune COO Holds 140K Shares, Boosting Insider Confidence in Neuro‑Diagnostic Pipeline

Insider Activity Highlights Confidence in AC Immune’s Diagnostic Pipeline

The most recent director‑dealing filing for AC Immune SA reveals that Chief Operating Officer Donati Piergiorgio maintains a substantial stake in the company, holding 141,120 common shares after a series of vested options. The transaction, dated March 20 2026, was executed at the closing price of $2.95—a level that has hovered near $3 for the past quarter. While the trade itself was not a sale, it signals that senior management remains comfortable with the company’s valuation and long‑term prospects.

A Pattern of Commitment

Donati’s ownership history—spanning multiple option grants that fully vested from 2028 through 2032 and a staggered vesting schedule beginning in 2024—demonstrates a sustained commitment to AC Immune. The cumulative effect of these holdings suggests that the COO’s personal wealth is tightly intertwined with the company’s future success, reducing the likelihood of a short‑term sell‑off. For investors, this alignment of interests is often viewed favorably, as it indicates that leadership’s incentives are linked to shareholder value rather than external pressures.

Implications for the Stock and the Pipeline

AC Immune’s recent clinical news—particularly the positive Phase 1 data for the PET tracer ACI‑19626—has already pushed the stock 12.6 % higher month‑to‑date, despite a broader weekly decline of 2.16 %. The company’s price‑earnings ratio remains negative at –3.7, reflecting the early‑stage nature of its product development. Yet the insider confidence, coupled with a 39.15 % annual gain and a 52‑week high of $4, suggests that the market is starting to price in the potential of its neurodegenerative disease diagnostics. A stable insider position could help cushion the stock against volatility that typically plagues biotech firms in the pre‑revenue phase.

What Investors Should Watch

• Option Vesting Milestones The COO’s options will fully vest through 2035, with quarterly installments beginning in 2024. These vesting dates are key to monitoring future insider trades that could signal changes in confidence or liquidity needs.

• Pipeline Milestones Completion of Phase 1 for ACI‑19626 in mid‑2026 and subsequent patient cohorts could trigger a significant upside if the tracer proves clinically valuable. The Phase 1 study demonstrated a favorable safety profile, with no dose‑limiting toxicities and a biodistribution pattern consistent with amyloid‑beta target engagement. These data are essential for the next‑stage Phase 2 trial, which will evaluate diagnostic accuracy against standard-of-care imaging and cerebrospinal fluid biomarkers.

• Market Sentiment Although current social‑media sentiment is neutral (0) and buzz is average, any shift in investor perception—particularly following regulatory filings or new data—could impact the share price more sharply. The company has submitted an investigational new drug (IND) application to the FDA for the PET tracer, and approval of this application would be a pivotal regulatory milestone.

Bottom Line

Donati Piergiorgio’s continued holding of over 140,000 shares, in the context of a promising diagnostic pipeline and modestly positive market trajectory, signals a stable insider outlook. For investors, this alignment of executive and shareholder interests may reduce short‑term risk and suggest that AC Immune is positioned for incremental gains as it advances its neurodegenerative disease programs.